Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
bUYoUT BIDing wars start in 18 months
It going to get real
The Big Boys will be on the bid !!!!!!!!!!!!!!!!!!
BuyOut $2.55
HammerTime !!!!!!!!!!
Is TuesDay News Day ??
Thanks for the reminder to buy yesterday.
The Perfect Storm:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio under 7.0
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. European distribution - Dexcel partnership approval by Israeli Health
__23. Full ownership of Adderall IR $ 335 Million
__24. Full ownership of Adderall XR $ 1.56 Billion
__25. Generic Concerta- $1.2 BILLION FDA submission
__26. $100 million in yearly revenue
__27. Generic Vyvanse Approval and Launch
__28. $200 million in yearly revenue
__29. Deep pocket partner for SequestOx
__30. Patented Unique ADF (w/o naltrexone)-- NDA
__31. Mikah ANDA (s)
__32. Undisclosed ANDAs/NDAs
__33. DollarLand PPS
__34. Big Pharma bid
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
This gets ‘em Goat Herders all out there steppin' and fetchin'
like their heads was on fire and their asses was catchin'
MIKAH is holding other half ownership of our Adderalls.
So when Elite can afford them they can take full ownership.
If any other Pharma got it we would never have be able to get it back
10.55%
Congrats !
Loks like you jumped in both feet
GL
Will a penny or so matter much at THE BUYOUT ??
You can try to time it if you fell lucky
GLTY
Locked $$ Loaded
IM LOADING UP TILL NEXT EARNINGS/ CC
YOU ??
I had to build it back after the Millionaire run of 2014.
This next one will be even more exciting.
GLTY
Im toppin' off for the next CC
What you doin"
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Let’s get the Adderalls and NeedleMovers paid for.
Get rid of their minimal debt then buyback.
It’s going to be way higher than where we are..
That could happen after Vyvance launch in a year
HammerTime !!
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio under 7.0
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. European distribution - Dexcel partnership approval by Israeli Health
__23. Full ownership of Adderall IR $ 335 Million
__24. Full ownership of Adderall XR $ 1.56 Billion
__25. Generic Concerta- $1.2 BILLION FDA submission
__26. $100 million in yearly revenue
__27. Generic Vyvanse Approval and Launch
__28. $200 million in yearly revenue
__29. Deep pocket partner for SequestOx
__30. Patented Unique ADF (w/o naltrexone)-- NDA
__31. Mikah ANDA (s)
__32. Undisclosed ANDAs/NDAs
__33. DollarLand PPS
__34. Big Pharma bid
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
5-10% of $10 billion combined IMS markets
Hyper sorry in advance for all the Trolls and Bullies on MBs
Will a Monster show its head ?
Secret MIKAH Program
signed back on December 3, 2018:
NOTE 20. RELATED PARTY AGREEMENTS WITH MIKAH PHARMA LLC
-- On December 3, 2018, the Company executed a development agreement with Mikah, pursuant to which Mikah and the Company will collaborate to develop and commercialize generic products including formulation development, analytical method development, bioequivalence studies and manufacture of development batches of generic products.
-- The Company received a total of $480,000 from Mikah as an advance payment for the purchase of pharmaceutical materials relating to future product development conducted pursuant to this agreement. This amount was recorded as a deposit and contained within the customer deposits financial statement line item on the consolidated balance sheet.
-- As of the date of this report, the Company has purchased raw materials with an aggregate cost of $542,214 pursuant to this agreement. As of March 31, 2020, the balance due from Mikah was $62,214 and was included in the financial statement line of prepaid expenses and other current assets on the accompanying consolidated balance sheet.
Lockin and Loadin for the next CC
HammerTime Near !
It’s about to Get Real. !!!!!
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
_
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
Tell us about your goats
I’m not sure if there is anyone home there?
Grow some
21 months
Here's what we are working with. Sorry for the confusion
Ive been zeroed in since 2 cents
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
__14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
Show your math.
🐢
Offers start @ $2.50
HammerTime
With all the needle movers launched $500 million revenues
I will take $5 and run.
GLTYa
.5 times
Half a lie ?
People are getting the BuyOut price and share price confused.
They will be very different till the BuyOut happens in 22 months
Ok if you say so ?
i USE AN iPAD AFTER work and the Emogies are all visible to me
ON MY LAP TOP EMOGIS LOOK LIKE SQUARES
Sorry Sharkey if I gave you a goat.
Hglis did I fix it ??
$10 bILLION combined IMS markets.:
5% = $$ 500,000,000
7.5% = $$$$750,000,000
10% = $$$$$$1,000,000,000
BULLISH ELTP
FDA Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
__14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!